Two high‑profile clinical developments this week delivered mixed news for enteroendocrine therapeutics. A large Alzheimer’s trial testing GLP‑1 drugs failed to meet endpoints, reporting no cognitive benefit in the evaluated population, a setback for efforts to repurpose obesity/diabetes agents for neurodegeneration. In contrast, tirzepatide produced clinically meaningful resolution of metabolic dysfunction‑associated steatohepatitis (MASH) without worsening fibrosis in a separate study, underscoring heterogeneous outcomes across incretin and dual‑agonist programs. The juxtaposition sharpens focus on indication‑specific biology and highlights the need for disease‑tailored development strategies, not broad class assumptions.